Quintiles credits IT advances for big deals; Merck Millipore eyes price hike;

> Quintiles CIO Richard Thomas says the CRO has boosted its IT capabilities of late, and that has helped bring in about $400 million in new business. Report

> CMO Merck Millipore is planning to hike its rates between 4% and 6% next year, citing rising costs. News

> Icon ($ICLR) is expanding its early-phase imaging services, unveiling new processes to save time in drug development. More

> AMRI has expanded its clinical supply agreement with Shire ($SHPG) for another 5 years. Neither company disclosed financial terms. Article

> Chinese CRO Tigermed is turning to Merge Healthcare ($MRGE) to streamline its clinical trial management. Release

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.